Viral Load Monitoring in HIV Care and Treatment

Viral load monitoring has become the cornerstone of contemporary HIV care, providing a direct measure of antiretroviral therapy (ART) efficacy by quantifying plasma HIV RNA. Regular assessment of viral load enables clinicians to detect treatment failure early, adjust regimens in a timely fashion and support adherence interventions. In high‐income settings, centralised laboratory testing with rapid turnaround underpins routine monitoring, but in low‐ and middle‐income regions logistical constraints have driven innovation in sample collection, transport and point‐of‐care assays. Approaches such as dried blood spots, plasma separation cards and decentralised rapid testing aim to bridge gaps in access, reduce result delays and empower differentiated care models. Thresholds of 50 to 1,000 copies per millilitre guide clinical decision‐making, with sustained suppression linked to reduced morbidity, mortality and onward transmission. Despite progress, challenges remain in the viral load cascade, including specimen transport, result utilisation, supply‐chain reliability and the capacity to switch to second‐line regimens when failure is confirmed. Continued optimisation of testing platforms and integrated care pathways is essential to achieve global HIV control targets.

Research from Nature Portfolio

Modelling work has demonstrated that viral‐load‐informed differentiated care can substantially reduce costs and clinic visits by stratifying patients according to suppression status. By tailoring visit frequency and focusing resources on those with elevated viral load, this strategy offers a sustainable approach to ART delivery in sub‐Saharan Africa, even when using dried blood spot specimens. In a retrospective cohort from Eritrea, analysis of over 5,000 patients on combined ART revealed a high rate of regimen substitutions driven by toxicity, drug shortages and treatment failure, while switches to second‐line therapy remained minimal. The study highlighted that inadequate viral load testing was likely responsible for delayed detection of virological failure, underscoring the need for reliable access to assays, robust supply chains and capacity building to support timely regimen modification.

Viral Load Monitoring in HIV Care and Treatment publication trend

The graph below shows the total number of articles in viral load monitoring in hiv care and treatment across all publications each year (not limited to Nature Index journals).

Technical terms

Viral load: Quantity of HIV RNA in blood, expressed as copies per millilitre, indicating treatment efficacy.
Point‐of‐care testing (POC): Diagnostic assays performed at or near the site of patient care to yield rapid results.
Dried blood spot (DBS): Filter paper samples containing dried capillary blood for remote viral load measurement.
Plasma separation card (PSC): A device that isolates plasma from capillary blood, facilitating decentralised viral load testing.
cART durability: The duration a combined antiretroviral therapy regimen remains effective without modification.

References

1. Sustainable HIV treatment in Africa through viral-load-informed differentiated care. Nature (2015).
2. Antiretroviral therapy regimen modification rates and associated factors in a cohort of HIV/AIDS patients in Asmara, Eritrea: a 16-year retrospective analysis. Scientific Reports (2023).
3. Assessment of the performance of the plasma separation card for HIV-1 viral load monitoring in South Africa. Journal of Clinical Microbiology (2024).
4. Impact of point‐of‐care HIV viral load and targeted drug resistance mutation testing on viral suppression among Kenyan pregnant and postpartum women: results from a prospective cohort study (Opt4Mamas). Journal of the International AIDS Society (2023).